EA201201453A1 - Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования - Google Patents

Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования

Info

Publication number
EA201201453A1
EA201201453A1 EA201201453A EA201201453A EA201201453A1 EA 201201453 A1 EA201201453 A1 EA 201201453A1 EA 201201453 A EA201201453 A EA 201201453A EA 201201453 A EA201201453 A EA 201201453A EA 201201453 A1 EA201201453 A1 EA 201201453A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparation
methods
drugs
proemulsia
taxans
Prior art date
Application number
EA201201453A
Other languages
English (en)
Other versions
EA027666B1 (ru
Inventor
Киициро Набета
Original Assignee
ТЕИКОКУ ФАРМА ЮСЭй, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕИКОКУ ФАРМА ЮСЭй, ИНК. filed Critical ТЕИКОКУ ФАРМА ЮСЭй, ИНК.
Publication of EA201201453A1 publication Critical patent/EA201201453A1/ru
Publication of EA027666B1 publication Critical patent/EA027666B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Предлагаются неводные лекарственные средства в форме проэмульсии на основе таксанов. Лекарственные средства в форме проэмульсии согласно примерам осуществления изобретения включают в себя таксан, масляный компонент, поверхностно-активный компонент и, возможно, неполный растворяющий компонент. Кроме того, предлагаются также способы приготовления и использования лекарственных средств в форме проэмульсии, а также лекарственные наборы, которые включают в себя лекарственные средства в форме проэмульсии.
EA201201453A 2010-05-03 2011-04-29 Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования EA027666B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33070510P 2010-05-03 2010-05-03
PCT/US2011/034586 WO2011139899A2 (en) 2010-05-03 2011-04-29 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same

Publications (2)

Publication Number Publication Date
EA201201453A1 true EA201201453A1 (ru) 2013-04-30
EA027666B1 EA027666B1 (ru) 2017-08-31

Family

ID=44858719

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201453A EA027666B1 (ru) 2010-05-03 2011-04-29 Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования

Country Status (21)

Country Link
US (2) US10842770B2 (ru)
EP (1) EP2566474B1 (ru)
JP (1) JP5824511B2 (ru)
KR (1) KR101752944B1 (ru)
CN (2) CN109745287A (ru)
AP (1) AP3552A (ru)
AU (1) AU2011248449B2 (ru)
BR (1) BR112012028037A2 (ru)
CA (1) CA2798180A1 (ru)
CO (1) CO6640232A2 (ru)
EA (1) EA027666B1 (ru)
ES (1) ES2652509T3 (ru)
IL (1) IL222785A0 (ru)
MX (1) MX341082B (ru)
MY (1) MY167224A (ru)
NZ (1) NZ603828A (ru)
SG (2) SG10201503234SA (ru)
TW (2) TW201526889A (ru)
UA (1) UA109275C2 (ru)
WO (1) WO2011139899A2 (ru)
ZA (1) ZA201208229B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JP5847942B2 (ja) * 2012-07-19 2016-01-27 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN104720070A (zh) * 2013-12-20 2015-06-24 财团法人食品工业发展研究所 微乳液预浓缩物和微乳液及其制备方法
TWI531318B (zh) 2013-12-20 2016-05-01 財團法人食品工業發展研究所 微乳液預濃縮物和微乳液暨其製備方法
CN106176599A (zh) * 2015-05-06 2016-12-07 江苏天士力帝益药业有限公司 一种卡巴他赛脂肪乳注射剂及其制备方法
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
CN110709105A (zh) * 2017-03-31 2020-01-17 技术防卫株式会社 载有药物的非水系组合物及其制备方法
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US561330A (en) * 1896-06-02 ljungstrom
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPS6328743A (ja) 1986-07-23 1988-02-06 Oi Seisakusho Co Ltd 自動車用シ−トスライド装置
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
JPH04164024A (ja) 1990-10-29 1992-06-09 Sankyo Co Ltd 医薬物質含有自己乳化型脂肪乳剤組成物の製造方法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
DE4208527A1 (de) 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
FR2691460B1 (fr) 1992-05-21 1994-07-22 Rhone Poulenc Rorer Sa Nouveaux derives du taxane, leur preparation et les compositions qui les contiennent.
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JP2880292B2 (ja) 1992-11-27 1999-04-05 ナプロ バイオセラピューティクス，インコーポレイテッド 注射可能組成物
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030133955A1 (en) 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
AU673057B2 (en) 1993-02-22 1996-10-24 Abraxis Bioscience, Llc Methods for (in vivo) delivery of biologics and compositionsuseful therefor
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5785976A (en) 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
FR2703049B1 (fr) 1993-03-22 1995-04-21 Rhone Poulenc Rorer Sa Procédé de purification des taxoïdes.
JP3526887B2 (ja) 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
ATE220894T1 (de) 1993-12-29 2002-08-15 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5616330A (en) 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4447770C2 (de) 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
KR100330373B1 (ko) 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6121245A (en) 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
AU744095B2 (en) 1997-03-27 2002-02-14 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
BRPI9810945B8 (pt) 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
CA2211949A1 (en) 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration
DE69804624T2 (de) 1997-07-29 2002-09-19 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
ATE225174T1 (de) 1997-07-29 2002-10-15 Upjohn Co Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
EP1039893B1 (en) 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
EP1059941B1 (en) 1998-03-05 2004-05-26 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2326485C (en) * 1998-04-01 2008-12-09 Rtp Pharma Inc. Anticancer compositions
JP2002513750A (ja) 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
IL139541A0 (en) 1998-05-20 2004-02-08 Liposome Co Inc Novel particulate formulations
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6638522B1 (en) 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1479382A1 (en) 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
TW422706B (en) 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6348215B1 (en) 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
WO2001030448A1 (en) 1999-10-27 2001-05-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US6638973B2 (en) 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
AU2001247726A1 (en) 2000-03-24 2001-10-08 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
JP3448006B2 (ja) 2000-03-29 2003-09-16 独立行政法人食品総合研究所 機能性エマルション
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
AU2001266272B2 (en) 2000-05-03 2005-09-15 Medigene Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US20020141966A1 (en) 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU1987802A (en) 2000-11-29 2002-06-11 Lyotropic Therapeutics Llc Solvent systems for pharmaceutical agents
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6815642B2 (en) 2001-12-19 2004-11-09 Delphi Technologies, Inc. Apparatus and method for heating a steering wheel
EP1509209A1 (en) 2002-05-23 2005-03-02 UMD, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE60316688T2 (de) 2002-08-02 2008-07-17 Nereus Pharmaceuticals, Inc., San Diego Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
ATE345277T1 (de) 2002-08-21 2006-12-15 Pharmacia Corp Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
WO2004032980A1 (en) 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
JP2006514698A (ja) 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
US6838569B2 (en) 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
CA2511486A1 (en) 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
KR20060034227A (ko) 2003-05-30 2006-04-21 에이알씨 파마시유티칼즈 인코포레이티드 다양한 제제를 사용하여 섬유성 유착을 억제하는 것에 관한약제학적 조성물 및 방법
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
DE602004014624D1 (de) 2003-08-29 2008-08-07 Yissum Res Dev Co Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln
DE602004020506D1 (de) 2003-12-12 2009-05-20 Quiral Quimica Do Brasil Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen für diese zusammensetzungen
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
WO2005115454A2 (en) 2004-05-07 2005-12-08 Massachusetts Institute Of Technology Methods and compositions for cancer treatment relating to brca1 brct domain recognition of phosphorylated bach1
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US7446126B2 (en) 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
BRPI0518239A2 (pt) 2004-10-29 2008-11-11 Novartis Ag composiÇÕes farmacÊuticas espontaneamente dispersÍveis
JP4734910B2 (ja) 2004-12-09 2011-07-27 日油株式会社 難水溶性薬剤用可溶化剤組成物
MX2007010394A (es) 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
ITMI20050614A1 (it) 2005-04-12 2006-10-13 Indena Spa Processo per la purificazione della 10-deacetilbaccatina iii dalla 10-deacetil-2-debenzoil-2-pentenoilbaccatina iii
CA2611592A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CN101291659A (zh) 2005-08-31 2008-10-22 阿布拉科斯生物科学有限公司 包含水难溶性药剂和抗微生物剂的组合物
NZ592132A (en) 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US20070142457A1 (en) 2005-10-12 2007-06-21 Alessandro Pontiroli Crystalline forms of docetaxel and processes for their preparation
US20100166872A1 (en) 2005-10-21 2010-07-01 Amarjit Singh Novel improved compositions for cancer therapy
AR057909A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
CZ300305B6 (cs) 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
AU2006331674A1 (en) 2005-12-21 2007-07-05 Tapestry Pharmaceuticals, Inc. Processes for taxane derivatives and intermediates useful therein
WO2007073383A1 (en) 2005-12-21 2007-06-28 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
KR100995390B1 (ko) 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
EP1808173A1 (en) 2006-01-12 2007-07-18 Matthias Dormeyer Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
BRPI0600285C1 (pt) 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
ATE446087T1 (de) 2006-01-23 2009-11-15 Yissum Res Dev Co Mikrokügelchen mit nanokapseln, die ein lipophiles arzneimittel enthalten
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
EP1998808A1 (en) 2006-02-21 2008-12-10 Dabur Pharma Limited Stable pharmaceutical composition of taxanes
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
JP2009533330A (ja) 2006-03-21 2009-09-17 ドクター レディズ ラボラトリーズ リミテッド ドセタキセルの多形体およびプロセス
US20070225510A1 (en) 2006-03-27 2007-09-27 Henri John T Convergent Process for the Synthesis of Taxane Derivatives
TW200817047A (en) 2006-04-03 2008-04-16 Teva Pharma Drug microparticles
CA2649335A1 (en) 2006-05-03 2007-11-08 I.Q.A., A.S. Pharmaceutical composition containing a taxane derivative, destined for the preparation of an infusion solution, method of preparation thereof and use thereof
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20110159111A1 (en) 2006-06-29 2011-06-30 Astex Therapeutics Limited Pharmaceutical combinations
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
JP5571380B2 (ja) 2006-07-24 2014-08-13 ルミナス バイオサイエンシズ，インコーポレイテッド オストワルド熟成を減少させた水不溶性の医薬品物質の固体ナノ粒子処方物
WO2008026048A2 (en) 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
KR101266549B1 (ko) 2006-10-20 2013-05-24 시노팜 싱가포르 피티이 리미티드 결정형 무수 도세탁셀을 제조하는 방법
EP2086508A2 (en) 2006-11-03 2009-08-12 MediGene Aktiengesellschaft Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
CN100998560A (zh) * 2006-12-27 2007-07-18 沈阳药科大学 多烯紫杉醇冻干乳剂及其制备方法
EP1946747A1 (en) 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
WO2008102374A1 (en) 2007-02-20 2008-08-28 Dabur Pharma Limited Amorphous form of docetaxel
EP2146692A1 (en) 2007-03-19 2010-01-27 Fresenius Kabi Oncology Limited Proliposomal and liposomal compositions
KR100878455B1 (ko) 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
US20080262078A1 (en) 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
FR2917088B1 (fr) 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
NZ581589A (en) * 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
CN101396354B (zh) 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
BRPI0817712A2 (pt) 2007-10-23 2015-03-31 Antisoma Res Ltd Sal de sódio cristalino de ácido 5,6-dimetil-oxo-xantano-4-acético, forma cristalina do mesmo, processos para preparar sal de sódio cristalino de ácido 5,6-dimetil-oxo-xantano-4-acético, e, para preparar forma cristalina, composição farmacêutica, método para preparar uma composição farmacêutica, uso de um sal de sódio cristalino de dmxaa, método para tratar câncer, kit de partes, e, formulação farmacêutica
US20090130198A1 (en) 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
UA100543C2 (ru) 2007-12-24 2013-01-10 Сан Фарма Адвансед Ресерч Компани Лимитед Нанодисперсия, включающая наночастицы, которые содержат производное таксана
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
CN101525321B (zh) 2008-03-06 2012-03-07 上海希迪制药有限公司 多烯紫杉醇倍半水结晶体及其制备方法
US20110293745A1 (en) 2008-03-14 2011-12-01 Sunesis Pharmaceuticals, Inc. Aurora kinase inhibitors
EP2271314A4 (en) 2008-03-28 2013-12-25 Univ Massachusetts COMPOSITIONS AND METHODS FOR PREPARING NANOEMULSIONS
AU2008354007A1 (en) 2008-04-04 2009-10-08 Robert Rodriguez Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents
RU2518240C2 (ru) 2008-04-18 2014-06-10 Ангиочем Инк. Композиция, на основе гидрофобных агентов и способ ее получения(варианты)
NZ590730A (en) 2008-07-23 2012-10-26 Bharat Serums & Vaccines Ltd Stable injectable oil-in-water docetaxel nanoemulsion
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
WO2010023321A1 (en) 2008-09-01 2010-03-04 Stragen Pharma S.A. Liquid formulation containing a taxane derivative
WO2010033771A2 (en) 2008-09-19 2010-03-25 Trustees Of The University Of Pennsylvania Modulators of hsp70/dnak function and methods of use thereof
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
US20110195030A1 (en) 2008-10-15 2011-08-11 The University Of North Carolina At Chapel Hill Nanoparticle compositions comprising liquid oil cores
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111831A1 (en) 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111845A1 (en) 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8798932B2 (en) 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
EP2358693A4 (en) 2008-11-20 2012-04-18 Reddys Lab Ltd Dr PREPARATION OF DOCETAXEL
CA2761042C (en) 2009-05-04 2019-11-12 Bengurion University Of The Negev Research And Development Authority Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery
JP5497336B2 (ja) 2009-05-20 2014-05-21 テクノガード株式会社 薬物を保持した脂肪粒子を含む非水系組成物およびその製造方法
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
AU2010261342A1 (en) 2009-06-19 2012-01-19 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
JP2013503166A (ja) 2009-08-25 2013-01-31 カーディオカイン・バイオファーマ・エルエルシー 不溶性剤を送達するための組成物
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
US8686165B2 (en) 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
KR101149600B1 (ko) 2009-12-31 2012-05-29 주식회사 삼양제넥스바이오 고순도 무수결정형 도세탁셀 제조방법
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012160568A1 (en) 2011-05-23 2012-11-29 Shilpa Medicare Limited Process for preparing docetaxel trihydrate polymorph

Also Published As

Publication number Publication date
CA2798180A1 (en) 2011-11-10
JP5824511B2 (ja) 2015-11-25
AU2011248449B2 (en) 2016-09-15
CN102970990A (zh) 2013-03-13
KR20130092992A (ko) 2013-08-21
ES2652509T3 (es) 2018-02-02
IL222785A0 (en) 2012-12-31
JP2013525485A (ja) 2013-06-20
TWI511726B (zh) 2015-12-11
ZA201208229B (en) 2013-07-31
UA109275C2 (uk) 2015-08-10
TW201204350A (en) 2012-02-01
EP2566474B1 (en) 2017-11-15
AP2012006564A0 (en) 2012-12-31
US20110269829A1 (en) 2011-11-03
MY167224A (en) 2018-08-14
NZ603828A (en) 2015-09-25
EA027666B1 (ru) 2017-08-31
MX2012012630A (es) 2013-05-20
TW201526889A (zh) 2015-07-16
AU2011248449A1 (en) 2012-12-20
CN109745287A (zh) 2019-05-14
MX341082B (es) 2016-08-08
EP2566474A4 (en) 2014-06-18
US20130052241A1 (en) 2013-02-28
AP3552A (en) 2016-01-18
SG10201503234SA (en) 2015-06-29
BR112012028037A2 (pt) 2016-08-02
EP2566474A2 (en) 2013-03-13
SG185389A1 (en) 2012-12-28
WO2011139899A3 (en) 2012-04-05
CO6640232A2 (es) 2013-03-22
KR101752944B1 (ko) 2017-07-03
US10842770B2 (en) 2020-11-24
WO2011139899A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
EA201201453A1 (ru) Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201390203A1 (ru) Способы получения тубулизинов
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
EA201370066A1 (ru) Модуляторы эстрогеновых рецепторов и их применение
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201890333A1 (ru) Противовирусные соединения
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201491996A1 (ru) Антагонисты st2l и способы их применения
EA201592214A1 (ru) Модулятор рецептора эстрогена и его применения
EA201492002A1 (ru) Противовирусные соединения
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA201600495A1 (ru) Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение
EA201590688A1 (ru) Производные n-проп-2-инилкарбоксамида и их применение в качестве антагонистов trpa1
EA201491002A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM